Our people

We believe in connections

Maria Juliet Livadiotis

Investment Director, CMS Ventures

Maria Juliet Livadiotis has a background in healthcare-focused investment banking, experience as a business and corporate development executive in biotechnology, and most recently, as academic co-inventor of a promising gene therapy candidate targeting a fatal paediatric disease called Tay-Sachs. 

Together with world renowned clinician and lysosomal disease expert, Professor Timothy Cox, Juliet co-founded Cambridge Gene Therapy, a Cambridge spinout aiming to accelerate development of their lead program, CAM-GM2, which has been granted orphan and fast track regulatory designations from the EMA and FDA.

Juliet joined CMS Ventures as an Investment Director in July 2020, with a particular interest in early stage ventures discovering advanced therapeutics in areas of compelling medical need.

Juliet holds an MPhil in Clinical Science from the University of Cambridge, an MBA from the University of Oxford and a BA in Economics from Princeton University.